Hemanext Inc.
About Hemanext Inc.
Products & Services
Specialties
Funding History
Debug: View Raw Funding Data
| # | Type | Amount Fields | Date Fields | Investors |
|---|---|---|---|---|
| 1 |
RT: SBIR Phase II Grant T: - FT: SBIR Phase II Grant |
A: 2900000 MR: - FA: $2.9M FAN: 2900000 |
D: 2025-10-14 FD: 2025-10-14 |
1 investors |
| 2 |
RT: Series B-3 T: - FT: Series B-3 |
A: 18900000 MR: - FA: $18.9 million FAN: 18900000 |
D: 2025-07-22 FD: 2025-07-22 |
- |
| 3 |
RT: Series B-2 Equity T: - FT: Series B-2 Equity |
A: 20000000 MR: - FA: just over $20 million FAN: 20000000 |
D: 2025-01-27 FD: 2025-01-27 |
- |
Growth Metrics
Team & Leadership
M. Shane Ray
CEO & Chief Commercial Officer
Andrew Dunham
Chief Scientific Officer
Eric Newman
Chief Financial Officer
Laurel Omert
Chief Medical Officer
Daan Kok
Head of BD & Strategy
Laura Daniels
VP Product Development
Recent News
Hemanext Inc. Announces New Product Launch
2 days agoCompany unveils innovative solution to transform the industry, expanding market reach and capabilities...
Read more →Leadership Team Expands with Industry Veteran
1 week agoNew executive brings 20+ years of experience to accelerate growth and strategic initiatives...
Read more →Company Recognized as Industry Leader
2 weeks agoReceives prestigious award for innovation and customer satisfaction in competitive market...
Read more →Key Competitors
Competitor Alpha
Series B · $50M raised
Competitor Beta
Series C · $120M raised
Competitor Gamma
Series A · $25M raised
Competitor Delta
Seed · $10M raised
Company Details
- Website
- hemanext.com
- Industries
- Biomedical Technology / Transfusion Medicine
- Company Size
- ~500 employees (est.)
Similar Companies
Discover AI-powered company recommendations based on industry, funding, and team profiles.
Upgrade to ProTechnology Stack
Discover the backend, frontend, and infrastructure technologies powering this company's products.
Upgrade to Pro